Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer.

Next Previous
X
Search
Trial Profile

A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Rectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms EXPERT-C; EXPERT-RCT

    • Most Recent Events

    • 11 Oct 2016 Results analysing KRAS mutations in circulating tumour DNA in patients with MRI-defined, high-risk, locally-advanced rectal cancer patients from the EXPERT-C trial, presented at the 41st European Society for Medical Oncology Congress
    • 23 May 2016 Results of a pooled analysis from EXPERT and EXPERT-C trials (n=269) published in the Annals of Oncology
    • 10 Jul 2015 Results of retrospective analysis published in the Annals of Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top